{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T19:23:01Z","timestamp":1785784981313,"version":"3.56.0"},"posted":{"date-parts":[[2023,4,21]]},"group-title":"In Review","reference-count":29,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:00:00Z","timestamp":1682035200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,4,7]]},"abstract":"<title>Abstract<\/title>\n        <p>Background\n Androgen deprivation therapy (ADT) with radiotherapy can benefit patients with localized prostate cancer. However, ADT can negatively impact quality of life and there remain no validated predictive models to guide its use.\nMethods\n Digital pathology image and clinical data from pre-treatment prostate tissue from 5,727 patients enrolled on five phase III randomized trials treated with radiotherapy +\/- ADT were used to develop and validate an artificial intelligence (AI)-derived predictive model to assess ADT benefit with the primary endpoint of distant metastasis. After the model was locked, validation was performed on NRG\/RTOG 9408 (n\u2009=\u20091,594) that randomized men to radiotherapy +\/- 4 months of ADT. Fine-Gray regression and restricted mean survival times were used to assess the interaction between treatment and predictive model and within predictive model positive and negative subgroup treatment effects.\nResults\n In the NRG\/RTOG 9408 validation cohort (14.9 years of median follow-up), ADT significantly improved time to distant metastasis (subdistribution hazard ratio [sHR]\u2009=\u20090.64, 95%CI [0.45\u20130.90], p\u2009=\u20090.01). The predictive model-treatment interaction was significant (p-interaction\u2009=\u20090.01). In predictive model positive patients (n\u2009=\u2009543, 34%), ADT significantly reduced the risk of distant metastasis compared to radiotherapy alone (sHR\u2009=\u20090.34, 95%CI [0.19\u20130.63], p\u2009&lt;\u20090.001). There were no significant differences between treatment arms in the predictive model negative subgroup (n\u2009=\u20091,051, 66%; sHR\u2009=\u20090.92, 95%CI [0.59\u20131.43], p\u2009=\u20090.71).\nConclusions\n Our data, derived and validated from completed randomized phase III trials, show that an AI-based predictive model was able to identify prostate cancer patients, with predominately intermediate-risk disease, who are likely to benefit from short-term ADT.<\/p>","DOI":"10.21203\/rs.3.rs-2790858\/v1","type":"posted-content","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T16:47:08Z","timestamp":1682095628000},"source":"Crossref","is-referenced-by-count":7,"title":["Artificial Intelligence Predictive Model for Hormone Therapy Use in Prostate Cancer"],"prefix":"10.21203","author":[{"given":"Daniel E","family":"Spratt","sequence":"first","affiliation":[{"name":"Case Western Reserve University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyi","family":"Tang","sequence":"additional","affiliation":[{"name":"Stanford University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilun","family":"Sun","sequence":"additional","affiliation":[{"name":"Case Western Reserve University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huei-Chung","family":"Huang","sequence":"additional","affiliation":[{"name":"Artera, Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmalyn","family":"Chen","sequence":"additional","affiliation":[{"name":"Artera, Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Mohamad","sequence":"additional","affiliation":[{"name":"University of California San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute Center for Prostate and Urologic Cancer"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan D","family":"Tward","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute, University of Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul L","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Brigham Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua M","family":"Lang","sequence":"additional","affiliation":[{"name":"University of Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingbin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Artera, Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinori","family":"Mitani","sequence":"additional","affiliation":[{"name":"Artera, Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffry P","family":"Simko","sequence":"additional","affiliation":[{"name":"University of California San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"DeVries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douwe van der","family":"Wal","sequence":"additional","affiliation":[{"name":"Artera, Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Pinckaers","sequence":"additional","affiliation":[{"name":"Artera, Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jedidiah M","family":"Monson","sequence":"additional","affiliation":[{"name":"Saint Agnes Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly A","family":"Campbell","sequence":"additional","affiliation":[{"name":"Saint John Regional Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Wallace","sequence":"additional","affiliation":[{"name":"University of Chicago Medicine Medical Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle J","family":"Ferguson","sequence":"additional","affiliation":[{"name":"Allan Blair Cancer Centre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Paul","family":"Bahary","sequence":"additional","affiliation":[{"name":"CHUM - Centre Hospitalier de l\u2019Universite de Montreal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward M","family":"Schaeffer","sequence":"additional","affiliation":[{"name":"Northwestern University Feinberg School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NRG Prostate Cancer AI","family":"Consortium","sequence":"additional","affiliation":[{"name":"NRG Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard M","family":"Sandler","sequence":"additional","affiliation":[{"name":"Cedars-Sinai Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuoc T","family":"Tran","sequence":"additional","affiliation":[{"name":"University of Maryland School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph P","family":"Rodgers","sequence":"additional","affiliation":[{"name":"NRG Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Esteva","sequence":"additional","affiliation":[{"name":"Artera, Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikiya","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Artera, Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix Y","family":"Feng","sequence":"additional","affiliation":[{"name":"University of California San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2021.08.031","author":"Jones CU","year":"2021","unstructured":"Jones CU, Pugh SL, Sandler HM, et al. Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG\/RTOG 9408 Randomized Clinical Trial. Int J Radiat Oncol Biol Phys [Internet] 2021;Available from: http:\/\/dx.doi.org\/10.1016\/j.ijrobp.2021.08.031"},{"issue":"5","key":"ref2","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.ijrobp.2004.08.047","article-title":"Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma\u2013long-term results of phase III RTOG 85 \u2013 31","volume":"61","author":"Pilepich MV","year":"2005","unstructured":"Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma\u2013long-term results of phase III RTOG 85 \u2013 31. Int J Radiat Oncol Biol Phys 2005;61(5):1285\u201390.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.8577","author":"D\u2019Amico AV","year":"2015","unstructured":"D\u2019Amico AV, Chen M-H, Renshaw A, Loffredo M, Kantoff PW. Long-term Follow-up of a Randomized Trial of Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer [Internet]. JAMA. 2015;314(12):1291. Available from: http:\/\/dx.doi.org\/10.1001\/jama.2015.8577"},{"issue":"27","key":"ref4","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1200\/JCO.21.00855","article-title":"Short Androgen Suppression and Radiation Dose Escalation in Prostate Cancer: 12-Year Results of EORTC Trial 22991 in Patients With Localized Intermediate-Risk Disease","volume":"39","author":"Bolla M","year":"2021","unstructured":"Bolla M, Neven A, Maingon P, et al. Short Androgen Suppression and Radiation Dose Escalation in Prostate Cancer: 12-Year Results of EORTC Trial 22991 in Patients With Localized Intermediate-Risk Disease. J Clin Oncol 2021;39(27):3022\u201333.","journal-title":"J Clin Oncol"},{"key":"ref5","author":"Kishan AU","unstructured":"Kishan AU, Sun Y, Hartman H, et al. Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis. Lancet Oncol [Internet] 2022 [cited 2022 Aug 29];23(2). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35051385\/"},{"issue":"5","key":"ref6","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","article-title":"Adverse effects of androgen deprivation therapy and strategies to mitigate them","volume":"67","author":"Nguyen PL","year":"2015","unstructured":"Nguyen PL, Alibhai SMH, Basaria S, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol 2015;67(5):825\u201336.","journal-title":"Eur Urol"},{"issue":"15","key":"ref7","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1200\/JCO.2007.14.9021","article-title":"Ten-year follow-up of radiation therapy oncology group protocol 92 \u2013 02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer","volume":"26","author":"Horwitz EM","year":"2008","unstructured":"Horwitz EM, Bae K, Hanks GE, et al. Ten-year follow-up of radiation therapy oncology group protocol 92 \u2013 02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008;26(15):2497\u2013504.","journal-title":"J Clin Oncol"},{"issue":"10","key":"ref8","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1200\/JCO.2003.05.004","article-title":"Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413","volume":"21","author":"Roach M","year":"2003","unstructured":"Roach M 3rd, DeSilvio M, Lawton C, et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 2003;21(10):1904\u201311.","journal-title":"J Clin Oncol"},{"issue":"4","key":"ref9","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1200\/JCO.2014.58.0662","article-title":"Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910","volume":"33","author":"Pisansky TM","year":"2015","unstructured":"Pisansky TM, Hunt D, Gomella LG, et al. Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910. J Clin Oncol 2015;33(4):332\u20139.","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2021.08.031","author":"Jones CU","year":"2021","unstructured":"Jones CU, Pugh SL, Sandler HM, et al. Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG\/RTOG 9408 Randomized Clinical Trial. Int J Radiat Oncol Biol Phys [Internet] 2021;Available from: http:\/\/dx.doi.org\/10.1016\/j.ijrobp.2021.08.031"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.0039","author":"Michalski JM","year":"2018","unstructured":"Michalski JM, Moughan J, Purdy J, et al. Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer [Internet]. JAMA Oncology. 2018;4(6):e180039. Available from: http:\/\/dx.doi.org\/10.1001\/jamaoncol.2018.0039"},{"issue":"2","key":"ref12","doi-asserted-by":"crossref","first-page":"134","DOI":"10.6004\/jnccn.2021.0008","article-title":"NCCN Guidelines Insights: Prostate Cancer, Version 1.2021: Featured Updates to the NCCN Guidelines","volume":"19","author":"Schaeffer E","year":"2021","unstructured":"Schaeffer E, Srinivas S, Antonarakis ES, et al. NCCN Guidelines Insights: Prostate Cancer, Version 1.2021: Featured Updates to the NCCN Guidelines. J Natl Compr Canc Netw 2021;19(2):134\u201343.","journal-title":"J Natl Compr Canc Netw"},{"key":"ref13","doi-asserted-by":"publisher","author":"Spratt DE","unstructured":"Spratt DE, Zhang J, Santiago-Jim\u00e9nez M, et al. Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer. J Clin Oncol [Internet] 2017 [cited 2021 Dec 15];Available from: http:\/\/dx.doi.org\/10.1200\/JCO.2017.74.2940","DOI":"10.1200\/JCO.2017.74.2940"},{"issue":"21","key":"ref14","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1158\/0008-5472.CAN-17-0629","article-title":"The Digital Slide Archive: A Software Platform for Management, Integration, and Analysis of Histology for Cancer Research","volume":"77","author":"Gutman DA","year":"2017","unstructured":"Gutman DA, Khalilia M, Lee S, et al. The Digital Slide Archive: A Software Platform for Management, Integration, and Analysis of Histology for Cancer Research. Cancer Res 2017;77(21):e75\u20138.","journal-title":"Cancer Res"},{"issue":"7","key":"ref15","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s42256-020-0200-7","article-title":"High-accuracy prostate cancer pathology using deep learning","volume":"2","author":"Tolkach Y","year":"2020","unstructured":"Tolkach Y, Dohmg\u00f6rgen T, Toma M, Kristiansen G. High-accuracy prostate cancer pathology using deep learning. Nature Machine Intelligence 2020;2(7):411\u20138.","journal-title":"Nature Machine Intelligence"},{"issue":"9","key":"ref16","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1001\/jamaoncol.2020.2485","article-title":"Development and Validation of a Deep Learning Algorithm for Gleason Grading of Prostate Cancer From Biopsy Specimens","volume":"6","author":"Nagpal K","year":"2020","unstructured":"Nagpal K, Foote D, Tan F, et al. Development and Validation of a Deep Learning Algorithm for Gleason Grading of Prostate Cancer From Biopsy Specimens. JAMA Oncol 2020;6(9):1372\u201380.","journal-title":"JAMA Oncol"},{"issue":"8","key":"ref17","doi-asserted-by":"crossref","first-page":"e407","DOI":"10.1016\/S2589-7500(20)30159-X","article-title":"An artificial intelligence algorithm for prostate cancer diagnosis in whole slide images of core needle biopsies: a blinded clinical validation and deployment study","volume":"2","author":"Pantanowitz L","year":"2020","unstructured":"Pantanowitz L, Quiroga-Garza GM, Bien L, et al. An artificial intelligence algorithm for prostate cancer diagnosis in whole slide images of core needle biopsies: a blinded clinical validation and deployment study. Lancet Digit Health 2020;2(8):e407\u201316.","journal-title":"Lancet Digit Health"},{"issue":"1","key":"ref18","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41746-022-00613-w","article-title":"Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials","volume":"5","author":"Esteva A","year":"2022","unstructured":"Esteva A, Feng J, van der Wal D, et al. Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials. NPJ Digit Med 2022;5(1):71.","journal-title":"NPJ Digit Med"},{"key":"ref19","unstructured":"Deep Residual Learning for Image Recognition [Internet]. [cited 2021 Dec 15];Available from: https:\/\/ieeexplore.ieee.org\/document\/7780459"},{"key":"ref20","author":"Chen X","year":"2020","unstructured":"Chen X, Fan H, Girshick R, He K. Improved Baselines with Momentum Contrastive Learning [Internet]. 2020 [cited 2021 Dec 15];Available from: http:\/\/arxiv.org\/abs\/2003.04297"},{"key":"ref21","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-030-05318-5","volume-title":"Automated Machine Learning: Methods, Systems, Challenges","author":"Hutter F","year":"2019","unstructured":"Hutter F, Kotthoff L, Vanschoren J. Automated Machine Learning: Methods, Systems, Challenges. Springer; 2019."},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.48550\/arXiv.1502.02127","author":"Claesen M","year":"2015","unstructured":"Claesen M, De Moor B. Hyperparameter Search in Machine Learning. 2015 [cited 2022 Aug 29];Available from: http:\/\/dx.doi.org\/10.48550\/arXiv.1502.02127"},{"issue":"446","key":"ref23","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A Proportional Hazards Model for the Subdistribution of a Competing Risk","volume":"94","author":"Fine JP","year":"1999","unstructured":"Fine JP, Gray RJ. A Proportional Hazards Model for the Subdistribution of a Competing Risk. J Am Stat Assoc 1999;94(446):496\u2013509.","journal-title":"J Am Stat Assoc"},{"issue":"15","key":"ref24","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJMe2114651","article-title":"Striving for Diversity in Research Studies","volume":"385","author":"Editors Rubin E","year":"2021","unstructured":"Editors, Rubin E. Striving for Diversity in Research Studies. N Engl J Med 2021;385(15):1429\u201330.","journal-title":"N Engl J Med"},{"key":"ref25","author":"Jones CU","unstructured":"Jones CU, Hunt D, McGowan DG, et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med [Internet] 2011 [cited 2021 Dec 15];365(2). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/21751904\/"},{"key":"ref26","unstructured":"Cancer of the Prostate - Cancer Stat Facts [Internet]. SEER. [cited 2023 Apr 10];Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html"},{"issue":"21","key":"ref27","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1093\/jnci\/djp335","article-title":"Use of archived specimens in evaluation of prognostic and predictive biomarkers","volume":"101","author":"Simon RM","year":"2009","unstructured":"Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009;101(21):1446\u201352.","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"ref28","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1097\/01.ju.0000158155.33890.e7","article-title":"The UCSF Cancer of the Prostate Risk Assessment (CAPRA) Score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy","volume":"173","author":"Cooperberg MR","year":"2005","unstructured":"Cooperberg MR, Pasta DJ, Elkin EP, et al. The UCSF Cancer of the Prostate Risk Assessment (CAPRA) Score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 2005;173(6):1938.","journal-title":"J Urol"},{"issue":"6","key":"ref29","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.eururo.2013.03.033","article-title":"Intermediate-risk Prostate Cancer Patients Undergoing Dose-escalated External-beam Radiation Therapy","volume":"64","author":"A New Risk Classification System for Therapeutic Decision Making with","year":"2013","unstructured":"A New Risk Classification System for Therapeutic Decision Making with Intermediate-risk Prostate Cancer Patients Undergoing Dose-escalated External-beam Radiation Therapy. Eur Urol 2013;64(6):895\u2013902.","journal-title":"Eur Urol"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-2790858\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-2790858\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T20:43:12Z","timestamp":1682109792000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-2790858\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,21]]},"references-count":29,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-2790858\/v1","relation":{},"subject":[],"published":{"date-parts":[[2023,4,21]]},"subtype":"preprint"}}